LIVN trades 18.5% below Wall Street's consensus target of $88.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LIVN achieves its forward estimates and maintains a stable P/E multiple of 17.2x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 2, 2026, LivaNova PLC (LIVN) has a Wall Street consensus price target of $88.50, based on estimates from 15 covering analysts. With the stock currently trading at $74.70, this represents a potential upside of +18.5%. The company has a market capitalization of $4.10B.
Analyst price targets range from a low of $76.00 to a high of $95.00, representing a 21% spread in expectations. The median target of $91.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LIVN trades at a trailing P/E of -16.8x and forward P/E of 17.2x. Analysts expect EPS to grow +30.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $1.8B | $15.92 | $26.00 | +63.3% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.5B | $20.55 | $38.00 | +84.9% | Buy | 8.5x | 10 |
 GKOSGlaukos Corporation | $9.6B | $163.17 | $192.89 | +18.2% | Buy | — | 25 |
 MDTMedtronic plc | $111.0B | $86.44 | $98.00 | +13.4% | Buy | 14.5x | 51 |
 ABTAbbott Laboratories | $168.5B | $96.71 | $121.50 | +25.6% | Buy | 17.5x | 41 |
 BSXBoston Scientific Corporation | $64.3B | $43.23 | $65.20 | +50.8% | Buy | 13.2x | 44 |
 SYKStryker Corporation | $104.7B | $273.03 | $372.39 | +36.4% | Buy | 18.2x | 52 |
 ELMDElectromed, Inc. | $236M | $28.50 | $48.50 | +70.2% | Buy | 23.4x | 5 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 ISRGIntuitive Surgical, Inc. | $141.7B | $401.24 | $491.15 | +22.4% | Buy | 37.2x | 57 |
Quick answers to the most common questions about buying LIVN stock.
LivaNova PLC (LIVN) has a consensus 12-month price target of $88.5, implying 18.5% upside from $74.7. The 15 analysts covering LIVN see moderate appreciation potential.
LIVN has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $88.5 implies 18.5% upside from current levels.
With a forward P/E of 17.1503x, LIVN trades at a relatively low valuation. The consensus target of $88.5 implies 18.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $95 for LIVN, while the most conservative target is $76. The consensus of $88.5 represents the median expectation. These targets typically reflect 12-month expectations.
LIVN is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LIVN stock forecast based on 15 Wall Street analysts shows a consensus price target of $88.5, with estimates ranging from $76 (bear case) to $95 (bull case). The median consensus rating is "Buy".
LIVN trades at a forward P/E ratio of 17.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on LIVN, with a "Buy" consensus rating and $88.5 price target (18.5% upside). 11 of 15 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LIVN analyst price targets range from $76 to $95, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $88.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.